CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company") announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. Eterna received formal confirmation on November 12th, 2024 from Nasdaq's Office of General Counsel, verifying that Eterna has met the market value of listed securities standard of at least $35 million, outlined in Listing Rule 5550(b)(2), and that Eterna is in compliance with all applicable continued listing standards. "With this achievement and the recent updates we've announced, we have transformed our company into a deb

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success. This restructuring includes reduction of its liabilities by discontinuing a longstanding lease, reducing the debt on its balance sheet and a new round of financing through a private investment in public equity (PIPE) investment. As a part of this financial restructuring, the Company has significantly reduced its liability by discontinuing a longstanding lease, resulting in an estimated $72 millio

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cellsThe presentation is on Saturday, May 11th, 2024 CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel wi

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cellsThe presentation is on Saturday, May 11th, 2024 CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel wil

Eterna reports the development of an mRNA-engineered iPSC line developed using UltraSlice™ to express a B2M-HLA-E fusion transgene in lieu of the endogenous B2M gene product to mimic native B2M expressionThe cells may prove useful for the rapid development of therapeutics with the potential for increased efficacy and safety owing to the immune-evasive nature of the cellsThe poster presentation is on Friday, May 10th 2024 CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Elizabeth Belche

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. "Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization," said Sanjeev Luther, President and CEO of Eterna. "We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineerin

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna's Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna's common stock (the "Stock Option") to its new President and Chief Executive Officer, Sanjeev Luther, effective January 1, 2024, the first date of his employment. The Stock Option was granted pursuant to the terms of Mr. Luther's employment agreement and as a material inducement to his joining Eterna as Presid

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer. James Bristol, Ph.D., Chairman of Eterna's Board of Directors, said, "We are excited to have Sanjeev take on the role of President and CEO of Eterna as we continue our work to support the deve

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. "Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization," said Sanjeev Luther, President and CEO of Eterna. "We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineerin

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer. James Bristol, Ph.D., Chairman of Eterna's Board of Directors, said, "We are excited to have Sanjeev take on the role of President and CEO of Eterna as we continue our work to support the deve

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of James Bristol, Ph.D., to its Board of Directors. "Dr. Bristol is a seasoned biopharmaceutical executive who has excelled as a corporate partner, board member, and strategic and technical advisor within our industry," said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. "We are thrilled to have him join our Board as we continue our mission of supporting the development of next-g

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors. "We are delighted to welcome Dorothy to our Board," said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. "Dorothy's extensive regulatory and legal expertise and experience as a Fortune 100 executive in the biopharmaceutical and healthcare sector will be invaluable as we continue to execute on our business and partnering strategies to

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Brant Binder and Richard Wagner, Ph.D. to its Board of Directors. Concurrently, Charles Cherington and Nicholas Singer have stepped down from the Board. "We are delighted to welcome Brant and Richard to our Board. Both bring a wealth of industry expertise, including founding and leading biotechnology companies with a proven history of delivering value for their stakeholders," said Matt Angel, Ph.D

Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it advances its mRNA cell engineering platform CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Jeff Karp, Ph.D. to Eterna's Scientific Advisory Board. Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, commented, "Jeff is a world-class expert in drug delivery and cell therapeutics

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp

CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules. The notes, which were issued at par, bear interest at a rate of 6.0% per year, payable quarterly, and mature in July 2028

Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics ("Exacis"). The acquisition complements Eterna's core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive g

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications – Entered into a sublease agreement with Bristol Myers Squibb to occupy 45,000 sq. ft. of lab and office space at Cambridge Crossing development in Cambridge, Massachusetts – Appointed Matt Angel, Ph.D. as Chief Executive Officer and President CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicine

Gainers Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion. Concord Medical Services (NYSE:CCM) stock rose 55.96% to $0.78. The company's market cap stands at $33.8 million. Microbot Medical (NASDAQ:MBOT) shares moved upwards by 40.79% to $1.41. The market value of their outstanding shares is at $20.2 million. Bio-Path Hldgs (NASDAQ:BPTH) shares moved upwards by 38.0% to $2.84. The market value of their outstanding shares is at $4.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) shares rose 23.45% to $11.95. The market value of their outstanding shares is at $668.4 mil

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cellsThe presentation is on Saturday, May 11th, 2024CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will pre

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells The presentation is on Saturday, May 11th, 2024CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will p

-SEC Filing

Gainers Revance Therapeutics (NASDAQ:RVNC) shares moved upwards by 16.5% to $6.0 during Friday's pre-market session. The company's market cap stands at $526.8 million. Eterna Therapeutics (NASDAQ:ERNA) shares increased by 15.78% to $1.98. The market value of their outstanding shares is at $10.7 million. Connect Biopharma Hldgs (NASDAQ:CNTB) stock rose 14.85% to $1.16. The market value of their outstanding shares is at $63.8 million. Celularity (NASDAQ:CELU) shares increased by 12.68% to $0.55. The company's market cap stands at $118.3 million. Trxade Health (NASDAQ:MEDS) shares rose 12.35% to $5.0. The company's market cap stands at $6.0 million. Windtree Therapeutics (NASDAQ:WINT) sha

Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) stock rose 48.3% to $0.82 during Thursday's pre-market session. The company's market cap stands at $6.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) stock rose 25.68% to $0.69. The market value of their outstanding shares is at $2.7 million. HOOKIPA Pharma (NASDAQ:HOOK) shares rose 20.59% to $0.75. The market value of their outstanding shares is at $74.1 million. Eterna Therapeutics (NASDAQ:ERNA) stock rose 19.16% to $1.99. The market value of their outstanding shares is at $10.7 million. Akso Health Group (NASDAQ:AHG) shares rose 18.9% to $1.95. The company's market cap stands at $44.5 million. OpGen (NASDAQ:OPGN) stock rose 18.03% to $0.

Gainers Aclarion (NASDAQ:ACON) shares rose 70.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $4.6 million. TRACON Pharma (NASDAQ:TCON) shares moved upwards by 47.92% to $0.28. The company's market cap stands at $8.6 million. Eterna Therapeutics (NASDAQ:ERNA) stock moved upwards by 22.8% to $1.87. The market value of their outstanding shares is at $10.0 million. Passage Bio (NASDAQ:PASG) shares increased by 21.23% to $0.92. The market value of their outstanding shares is at $50.4 million. NuCana (NASDAQ:NCNA) stock moved upwards by 16.6% to $0.4. The company's market cap stands at $21.2 million. Regional Health Props (AMEX:RHE) stock

- SEC Filing

Gainers Aclarion (NASDAQ:ACON) shares rose 75.8% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.8 million. Longeveron (NASDAQ:LGVN) stock rose 43.07% to $2.79. The market value of their outstanding shares is at $66.2 million. Passage Bio (NASDAQ:PASG) shares moved upwards by 25.16% to $0.95. The company's market cap stands at $52.0 million. Dare Bioscience (NASDAQ:DARE) shares moved upwards by 23.24% to $0.42. The company's market cap stands at $41.5 million. Eterna Therapeutics (NASDAQ:ERNA) shares moved upwards by 22.8% to $1.87. The market value of their outstanding shares is at $10.0 million. Kintara Therapeutics (NASDAQ:KTRA)